Key result
Treatment with tyrosine kinase inhibitors significantly increased the prevalence of QTc prolongation from 19.1% to 34.8% in non-diabetic patients and from 21.7% to 40% in diabetic patients.
Why the study?
Does the use of tyrosine kinase inhibitors increase the prevalence of QTc prolongation in diabetic and non-diabetic cancer patients?
Observational (n=313)
No
Does the use of tyrosine kinase inhibitors increase the prevalence of QTc prolongation in diabetic and non-diabetic cancer patients?
Absolute Event Rate: 34.8% vs 19.1%
p-value: p=<0.001
TKI use significantly increases the risk of QTc prolongation in both diabetic and non-diabetic patients, and this risk is not mitigated by standard cardiovascular risk factor modifications.
May warrant QTc monitoring during TKI therapy in cancer patients; hypothesis-generating for mitigation beyond standard CVD risk factor modification.
Use of TKIs is associated with a significantly increased risk of QTc prolongation for patients, particularly when patients are diabetic. Modification of risk factors for CVD does not significantly affect the prevalence of QTc prolongation caused by TKIs.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2021) conducted an observational in Cancer patients taking Tyrosine Kinase Inhibitors (n=313). Tyrosine Kinase Inhibitors (TKIs) vs. Before TKI treatment (baseline) was evaluated on Prevalence of QTc prolongation (>450 ms) in non-diabetic patients (p=<0.001). Treatment with tyrosine kinase inhibitors significantly increased the prevalence of QTc prolongation from 19.1% to 34.8% in non-diabetic patients and from 21.7% to 40% in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: